Moleculin Biotech Celebrates WHO's Approval of Naxtarubicin
Annamycin shows promise as a safer and more effective alternative to current treatments for challenging cancers.
Significant Milestone Achieved
HOUSTON, Moleculin Biotech, Inc. (Nasdaq: MBRX), a pioneering pharmaceutical company, proudly announces that the World Health Organization (WHO) has approved the name "naxtarubicin" for its innovative drug Annamycin. This designation marks a pivotal moment in the journey of Annamycin, designed to tackle hard-to-treat cancers like acute myeloid leukemia (AML) and soft tissue sarcomas (STS).
Annamycin: A New Hope for Cancer Treatment
Annamycin, the focus of ongoing research, is seen as a potential game-changer in cancer therapy. Unlike traditional anthracyclines, which can have serious side effects, Annamycin is being engineered to avoid cardiotoxicity. This makes it a promising candidate for treatment regimens where cardiac health is a concern.
The Path Forward with the MIRACLE Trial
The company’s team is enthusiastic about the ongoing pivotal, adaptive Phase 3 clinical trial known as the "MIRACLE" trial. This study is designed to evaluate Annamycin's effectiveness in patients suffering from relapsed and refractory AML. With initial results expected by mid-2025, many anticipate that these outcomes could significantly influence treatment protocols in hematology.
Trial Details and Patient Recruitment
The trial includes diverse patient populations across the globe, with sites established in the US, Europe, and the Middle East. Patient recruitment is actively in progress, and the results will serve as a key determinant for the future commercialization of this therapy.
Understanding WHO's INN Naming Process
The approval process ascertains that each drug has a unique, globally accepted name, promoting safe prescription practices and regulatory clarity. Walter Klemp, Chairman and CEO, emphasized how this new name plays a crucial role in the journey toward making Annamycin accessible to the patients who need it most.
Advantages of Naxtarubicin
In addition to its potential therapeutic advantages, the Food and Drug Administration (FDA) has granted Annamycin both Fast Track Status and Orphan Drug Designation for AML and STS. These designations signify expedited development pathways primarily aimed at benefiting patients with rare diseases.
About Moleculin Biotech
Moleculin Biotech is on the forefront of innovation in cancer treatment. The company's portfolio includes not only Annamycin but also emerging therapies capable of addressing various malignancies and viral infections. For instance, WP1066, currently under investigation, shows promise as an immune modulator targeting brain tumors and other cancers, while WP1122 serves the dual purpose of addressing pathogenic viruses and specific cancer indications.
Community and Investor Engagement
The company encourages ongoing dialogue with both the medical community and investors, recognizing that transparency is vital for engagement and investment in these critical developments.
For investor inquiries, please reach out to:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
MBRX@jtcir.com
Frequently Asked Questions
What is naxtarubicin?
Naxtarubicin is the newly approved International Non-Proprietary Name for Annamycin, a novel cancer treatment.
What cancers does Annamycin target?
Annamycin primarily targets relapsed or refractory acute myeloid leukemia and soft tissue sarcomas.
When are the initial data results expected from the MIRACLE trial?
The initial results from the MIRACLE trial are expected in the second half of 2025.
What designations has Annamycin received from the FDA?
Annamycin has received Fast Track Status and Orphan Drug Designation from the FDA for specific cancer treatments.
How can I stay updated on Moleculin Biotech's progress?
You can stay informed by visiting the company's website and following their social media channels.
